Obesity, Ozempic, and Medicalization Through Pharmaceuticalization

Authors

  • Alessandro Demichelis IMT School for Advanced Studies Lucca, Italy

DOI:

https://doi.org/10.4454/mefisto.10-1.1648

Keywords:

Medicalization, Pharmaceuticalization, Ozempic, Semaglutide, Obesity

Abstract

Obesity and overweight globally affect billion of people, and have an economic impact measurable in trillion of dollars. In the recent years, two things have changed how we treat and see these conditions. First, the development of semaglutide-based therapies has introduced in the market an effective treatment for obesity that (so far) present drastically reduced side effects compared to previous ones. Second, the consensus of the medical community has slowly converged toward considering obesity a disease. This process is particularly interesting when placed within the discourses over medicalization, i.e. the transformation of non-medical conditions in medical ones, and pharmaeuticalization, i.e. the transformation of human conditions not managed with drugs in ones which are. Pharmaceuticalization has been often considered to follow, logically and temporally, medicalization. This paper presents the impact that semaglutide had on the redefinition of obesity as a disease, and claims that this case shows how pharmaceuticalization can preceed, and shape, medicalization.

Published

2026-11-12

Issue

Section

Focus